These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32651105)

  • 41. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
    Wollenberg A; Howell MD; Guttman-Yassky E; Silverberg JI; Kell C; Ranade K; Moate R; van der Merwe R
    J Allergy Clin Immunol; 2019 Jan; 143(1):135-141. PubMed ID: 29906525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.
    Uchida H; Kamata M; Kato A; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Am Acad Dermatol; 2021 Feb; 84(2):547-550. PubMed ID: 32479977
    [No Abstract]   [Full Text] [Related]  

  • 43. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
    Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
    J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL; Van Syoc M; Chanda S; Zane LT
    Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of the histamine H
    Werfel T; Layton G; Yeadon M; Whitlock L; Osterloh I; Jimenez P; Liu W; Lynch V; Asher A; Tsianakas A; Purkins L
    J Allergy Clin Immunol; 2019 May; 143(5):1830-1837.e4. PubMed ID: 30414855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
    JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
    Murata Y; Song M; Kikuchi H; Hisamichi K; Xu XL; Greenspan A; Kato M; Chiou CF; Kato T; Guzzo C; Thurmond RL; Ohtsuki M; Furue M
    J Dermatol; 2015 Feb; 42(2):129-39. PubMed ID: 25491792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Villegas SC; Dima L
    Am J Ther; 2023 Mar-Apr 01; 30(2):e117-e125. PubMed ID: 36799867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies.
    Kim HS; Lee JH; Roh KH; Jun HJ; Kang KS; Kim TY
    Stem Cells; 2017 Jan; 35(1):248-255. PubMed ID: 27256706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea.
    Won CH; Seo PG; Park YM; Yang JM; Lee KH; Sung KJ; Park CW; Kim DW; Chang HS; Won YH; Kim KH
    J Dermatolog Treat; 2004 Jan; 15(1):30-4. PubMed ID: 14754647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
    Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
    J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
    Guttman-Yassky E; Simpson EL; Reich K; Kabashima K; Igawa K; Suzuki T; Mano H; Matsui T; Esfandiari E; Furue M
    Adv Ther; 2024 Mar; 41(3):928-931. PubMed ID: 38185777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.
    Mihara R; Kabashima K; Furue M; Nakano M; Ruzicka T
    J Dermatol; 2019 Aug; 46(8):662-671. PubMed ID: 31166620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
    Lin YK; Chang SH; Yang CY; See LC; Lee BH; Shih IH
    J Ethnopharmacol; 2020 Mar; 250():112477. PubMed ID: 31838180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dupilumab for the Treatment of Atopic Dermatitis.
    Ferreira S; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.
    Yamauchi T; Sasaki S; Lee ES; Tamura T; Seki M; Miwa T; Kobayashi K; Saruta Y; Kitami Y; Sueki H; Watanabe H
    Int J Dermatol; 2021 Feb; 60(2):190-195. PubMed ID: 32989751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.